Concept · Learn
Peptide Cheat Sheet & Dosing Chart (2026)
This peptide cheat sheet puts commonly searched compounds beside doses reported in FDA labels or human research, not doses chosen for an individual. The numbers are inseparable from route, formulation, study population, and purpose. Research-market compounds without a defensible human dose are marked that way rather than given a confident-looking guess.
How should you read this peptide dosing chart?
This peptide dosing chart is a source map, not a protocol: read the “basis” column before reading the number. An FDA label describes one regulated product for a stated use. A human study dose describes what researchers tested under that study’s conditions. A community-reported amount is anecdotal, even if thousands of forum comments repeat it.
The labels matter because three phrases that look similar are not interchangeable:
- Labeled dose means the dose in prescribing information for a specific approved product and indication.
- Human research dose means an amount administered in a cited study, not a general recommendation.
- No established human dose means reliable clinical evidence does not supply a usable number for that compound and purpose.
What doses appear on the peptide cheat sheet?
The peptide cheat sheet below favors traceable figures over a longer, shakier list. Semaglutide, tirzepatide, and tesamorelin have product-specific FDA labels. CJC-1295 and ipamorelin have human pharmacology studies but no FDA-approved bodybuilding or anti-aging dose. BPC-157 and TB-500 do not have a clinically established human dosing schedule.
| Compound | Dose reported by the source | Route and timing | Basis and limit |
|---|---|---|---|
| Semaglutide | WEGOVY injection starts at 0.25 mg and escalates every 4 weeks; the usual maintenance dose is 2.4 mg | Subcutaneous, once weekly | FDA label via DailyMed; applies to that product and indication |
| Tirzepatide | 2.5 mg is the labeled starting dose; labeled maintenance doses are product- and indication-specific, up to 15 mg | Subcutaneous, once weekly | FDA labels via DailyMed; initiation is not a maintenance dose |
| Tesamorelin | EGRIFTA SV: 1.4 mg | Subcutaneous, once daily | EGRIFTA SV label; formulation-specific |
| CJC-1295 | Human trials included 30 or 60 mcg/kg dose groups | Subcutaneous; single and repeated weekly or biweekly study dosing | Healthy-adult pharmacology study; hormone response, not a bodybuilding protocol |
| Ipamorelin | 4.21–140.45 nmol/kg across five dose-escalation groups | Intravenous infusion over 15 minutes, once per study session | Healthy-volunteer pharmacology study; not comparable to a home subcutaneous schedule |
| BPC-157 | No established human dose for healing or recovery | No validated clinical schedule | PubMed’s BPC-157 record does not establish a standard treatment dose |
| TB-500 | No established human dose | No validated clinical schedule | PubMed search results do not turn thymosin beta-4 research into a TB-500 protocol |
The units are part of the evidence. CJC-1295 was studied in micrograms per kilogram, while the ipamorelin experiment used nanomoles per kilogram and an intravenous infusion. Converting either line into a fixed subcutaneous amount would create a new protocol that the cited study did not test.
Why are approved and research-only doses separated?
Approved and research-only doses answer different questions. A label tells clinicians how a particular manufactured drug was reviewed for a defined condition. A phase 1 pharmacology study may ask only how long a compound remains in blood or whether a hormone rises. The study can answer that narrow question without proving an effective dose for fat loss, healing, muscle gain, or longevity.
This distinction is especially useful around growth-hormone peptides. CJC-1295 raised growth hormone and insulin-like growth factor 1 in healthy adults, but the trial did not establish a muscle-building dose. Ipamorelin triggered a growth-hormone pulse during intravenous testing; the study did not validate the fixed subcutaneous schedules circulated online.
Does a common community dose count as evidence?
A common community dose counts as anecdotal evidence of what people discuss, not clinical evidence that the amount is effective or safe. Repetition can reveal a convention without validating it. Community posts also blur salt forms, vial contents, routes, body sizes, cycle lengths, and whether the label accurately identifies the powder.
That is why this peptide dosage cheat sheet leaves BPC-157 and TB-500 blank instead of laundering forum consensus into medical-looking numbers. “Research use only” does not describe an FDA-reviewed human product; the research-use-only explainer covers what that label does and does not mean.
How do milligrams, micrograms, and syringe units relate?
Milligrams and micrograms measure mass; syringe units measure liquid volume. The relationship depends on how much compound and diluent are actually in the vial. A chart cannot safely convert those values without the vial strength and final volume, and copying somebody else’s syringe-unit number can produce a tenfold error when concentrations differ.
Use the reconstitution calculator for that arithmetic rather than treating this page as a mixing worksheet. The calculator does not decide a dose. The peptide cheat sheet supplies the source context; the calculator only converts a known mass and concentration into volume.
What can make the same dose mean something different?
The same printed dose can mean something different when the formulation, route, frequency, or person changes. Tesamorelin is the clean example: EGRIFTA SV’s 1.4 mg dose belongs to its 2 mg-per-vial formulation. Older tesamorelin formulations used different preparation instructions, so matching the compound name while ignoring the product can still produce the wrong answer.
Body-weight dosing adds another trap. A research dose written as mcg/kg is not a fixed amount, and changing from intravenous infusion to subcutaneous injection can change exposure. Dose escalation also matters: semaglutide and tirzepatide labels start low partly to reduce gastrointestinal adverse reactions during titration. The maintenance number alone leaves out half the story.
What is the safest takeaway from a peptide dosage cheat sheet?
The safest takeaway is to treat every number as a citation with conditions attached. Match the exact compound, formulation, route, frequency, population, and research goal before comparing rows. If those details do not match, the numbers are not equivalent, however tidy the table looks.
This peptide cheat sheet is most useful for spotting evidence gaps quickly. Approved products have detailed, product-level instructions. Early human studies provide bounded experimental doses. Research-market compounds may have no validated human schedule at all. That empty cell is useful information, and considerably more honest than a decimal point wearing a lab coat.